PTC Therapeutics said it cannot resolve differences it has with the FDA in interpreting clinical trial data for Translarna, a drug it developed for Duchenne muscular dystrophy. The rare disease drug developer’s decision to withdraw Translarna’s FDA submission comes nearly a year after a negative European regulatory decision for the drug.
The post PTC Therapeutics Ends Bid to Seek FDA Approval for Rare Muscle Disease Drug appeared first on MedCity News.
New threat actor UAT-9921 deploys VoidLink against enterprise sectors – Security Affairs
New threat actor UAT-9921 deploys VoidLink against enterprise sectors Security Affairs
